Full Text View
Tabular View
No Study Results Posted
Related Studies
Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy
This study has been terminated.
Study NCT00157508   Information provided by Mario Negri Institute for Pharmacological Research

First Received on September 8, 2005.   Last Updated on November 18, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 2 Diabetes
Early Nephropathy
Additional conditions recognized in this trial
Diabetes Mellitus
Diabetes Mellitus, Type 2
Kidney Diseases
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Urologic Diseases
Interventions listed in this trial
nitroaspirin
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cysteine Proteinase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Protease Inhibitors
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Mario Negri Institute for Pharmacological Research


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services